Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN1 | O60741 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23623487 | 0.85 | KCNK3 (0.44) | HCN1KCNK3KCNK9F2ROPRM1 | |
| SCHEMBL23611736 | 0.83 | S1PR1 (0.41) | HCN1KCNK3KCNK9F2RROCK2 | |
| SCHEMBL23623491 | 0.82 | OPRM1 (0.42) | HCN1KCNK3KCNK9F2ROPRM1 | |
| SCHEMBL23623646 | 0.82 | HCN1 (0.41) | HCN1KCNK3KCNK9F2ROPRM1 | |
| SCHEMBL23623811 | 0.81 | KCNK3 (0.50) | HCN1KCNK3KCNK9MAPTF2R | |
| SCHEMBL23623645 | 0.81 | HCN1 (0.43) | HCN1KCNK3KCNK9F2RROCK2 | |
| SCHEMBL23645022 | 0.81 | MAPT (0.38) | HCN1KCNK3KCNK9MAPTF2R | |
| SCHEMBL23623809 | 0.80 | PTGES (0.41) | HCN1KCNK3KCNK9F2RROCK2 | |
| SCHEMBL23623344 | 0.80 | OPRM1 (0.42) | HCN1KCNK3KCNK9F2ROPRM1 | |
| SCHEMBL31461705 | 0.80 | RXFP1 (0.42) | HCN1KCNK3KCNK9F2RROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091590-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BERG LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| WO-2021138540-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | BERG LLC (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091447-B2 | UBE2K modulators and methods for their use | UBE2N, UBE2B, UBE2E1 | HCN1 4832/4885KCNK3 2414/4885KCNK9 2438/4885 |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | HCN1 4832/4885KCNK3 2414/4885KCNK9 2438/4885 |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | HCN1 4832/4885KCNK3 2414/4885KCNK9 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.